PepFinder
somatostatin analogCancer Research Peptides

Octreotide (Sandostatin)

A synthetic octapeptide analog of somatostatin with improved half-life (90-120 min vs 2-3 min). FDA-approved for acromegaly, carcinoid tumors, and VIPomas. Also used as a targeting vector for radiolabeled peptide therapy.

somatostatin-analogtumor-treatmentacromegalycarcinoidFDA-approved
3D Structure
3D Structure
1019.24 Da
Molecular Weight1,019.24 Da
FormulaC49H66N10O10S2
PubChem CID448601
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
Intensity5106437769091041m/z1019.5
ESI-MS (computed)
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity data
Lab Reports
0 reports on file
Summary

A synthetic octapeptide analog of somatostatin with improved half-life (90-120 min vs 2-3 min). FDA-approved for acromegaly, carcinoid tumors, and VIPomas. Also used as a targeting vector for radiolab…